SYK.NYSEStryker CORP
DEF: Stryker Reports Strong 2025 Financials, Boosts Shareholder Value
Sentiment:
Proxy Statement
Stryker Corporation's latest proxy statement reveals robust 2025 financial performance, strong executive compensation alignment, and key corporate governance updates ahead of its 2026 Annual Meeting.
Better than expectedNet sales increased by 11.2%, indicating strong revenue growth.Adjusted net earnings per diluted share grew by 11.8%, reflecting enhanced profitability.The 2023 Performance Stock Units (PSUs) paid out at 200% of target, significantly exceeding expectations for long-term performance metrics.Cash, cash equivalents, and marketable securities increased by 9.5%, demonstrating improved liquidity.
Summary
- Stryker reported net sales of $25.116 billion in 2025, an 11.2% increase from $22.595 billion in 2024.
- Net earnings grew 8.5% to $3.246 billion in 2025, up from $2.993 billion in 2024.
- Adjusted net earnings increased by 12.1% to $5.267 billion in 2025, compared to $4.700 billion in 2024.
- Adjusted net earnings per diluted share rose 11.8% to $13.63 in 2025, from $12.19 in 2024.
- Dividends paid per share of common stock increased 5.0% to $3.36 in 2025.
- Cash, cash equivalents, and marketable securities reached $4.100 billion, a 9.5% increase from $3.743 billion in 2024.
- Named Executive Officers (NEOs) received an average of 100% of their target annual bonus for 2025 performance.
- Performance Stock Units (PSUs) granted in 2023 for the 2023-2025 period achieved a 200% payout, reflecting maximum goals for average reported net sales growth relative to peers and average adjusted net earnings per diluted share growth.
- The 2026 Annual Meeting of Shareholders will be held virtually on May 6, 2026, to elect ten directors, ratify Ernst & Young LLP as the independent auditor, and conduct an advisory vote on NEO compensation.
Sentiment
Score: 9
Explanation: StockSavvy.ai views this filing very positively, reflecting strong 2025 financial results, exceptional achievement of long-term performance goals, and robust corporate governance practices that align management with shareholder interests.
Positives
- Net sales increased by a strong 11.2% to $25.116 billion in 2025.
- Adjusted net earnings per diluted share grew significantly by 11.8% to $13.63.
- The 2023 Performance Stock Units (PSUs) achieved a maximum payout of 200% of target, indicating exceptional long-term financial performance against pre-established goals.
- NEO annual bonuses averaged 100% of target, reflecting achievement of core performance goals.
- Cash, cash equivalents, and marketable securities increased by 9.5% to $4.100 billion, demonstrating strong liquidity.
- Dividends paid per share increased by 5.0% to $3.36, benefiting shareholders.
- The company maintains robust corporate governance practices, including annual director elections, majority voting, a strong Lead Independent Director role, and independent board committees.
- All non-employee directors and NEOs subject to ownership guidelines were in compliance as of December 31, 2025.
Negatives
- The consolidated adjusted operating income margin target goal of 26.44% was not achieved for overachievement bonus measures, resulting in no payout for these measures despite strong overall performance.
- The company's financial performance was adversely impacted by tariffs in 2025, though no adjustments were made to the calculated bonus payout for NEOs.
Risks
- Forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially and adversely from expectations.
- A detailed discussion of risks, uncertainties, and changes in circumstances is included in the section titled Risk Factors in the Annual Report on Form 10-K for the year ended December 31, 2025.
- The company's executive compensation programs are assessed to ensure they do not encourage excessive risk-taking, with a 2025 assessment concluding no material adverse effect is likely.
- An updated risk assessment of the sales compensation program commenced in the second half of 2025 and is scheduled to be finalized in 2026, with findings to be disclosed in the 2027 proxy statement.
Future Outlook
Stryker's future outlook includes the continued focus on long-term growth and profitability, with executive compensation programs designed to align management interests with shareholder value creation. The company will hold its 2026 Annual Meeting to elect directors and ratify its independent auditor. Long-term incentive plans, such as the 2026 performance stock units, are tied to achieving three-year average adjusted net earnings per diluted share growth and relative net sales growth, with payouts in early 2029. Non-employee director compensation and stock ownership guidelines are also set to increase in May 2026.
Management Comments
- Our executive pay programs have played a significant role in our ability to attract, motivate and retain the experienced executive team that has successfully driven our financial results over time.
- The Compensation and Human Capital Committee continues to believe that our executive compensation policies, practices and programs are appropriate and, in light of the results of the advisory vote, believes our shareholders feel the same.
- We believe that our executive compensation program, which is a key component of our ability to attract, motivate and retain talented, qualified executives, should be designed to provide a meaningful level of total compensation that is aligned with organizational and individual performance and with the interests of our shareholders.
Industry Context
StockSavvy.ai notes that Stryker's strong 2025 financial performance, particularly in net sales and adjusted net earnings growth, indicates a robust position within the competitive medical technology industry. The company's emphasis on performance-based executive compensation, with a significant portion tied to long-term equity incentives and challenging financial goals, aligns with best practices aimed at sustained business growth and shareholder value creation, a critical factor in a capital-intensive and innovation-driven sector.
Comparison to Industry Standards
- Stryker's average reported net sales growth for the 2023-2025 performance period achieved the 94th percentile relative to a comparison group of 18 companies, including Abbott Laboratories, GE HealthCare Technologies Inc., Johnson & Johnson (MedTech Segment), Medtronic plc, and Zimmer Biomet Holdings, Inc., demonstrating superior sales performance.
- The company's average adjusted net earnings per diluted share growth of 13.4% for the 2023-2025 period exceeded the maximum goal of 12.0%, outperforming internal targets and likely positioning it favorably against industry peers in profitability growth.
- The 2025 executive compensation structure, with 87% of total direct compensation for NEOs tied to variable performance and stock-based compensation, is competitive and aligns with the industry trend of linking executive pay to company performance and shareholder returns.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chair and Chief Executive Officer | Chair, Chief Executive Officer and President (Kevin A. Lobo) | Chair and Chief Executive Officer (Kevin A. Lobo) | January 1, 2026 | Title change |
| Vice President, Chief Financial Officer | Vice President, Group Chief Financial Officer for Orthopaedics (Preston W. Wells) | Vice President, Chief Financial Officer (Preston W. Wells) | April 1, 2025 | Promotion |
| President and Chief Operating Officer | Group President, Orthopaedics (Spencer S. Stiles) | President and Chief Operating Officer (Spencer S. Stiles) | January 1, 2026 | Promotion |
| Advisor to the Chief Executive Officer | Vice President, Chief Financial Officer (Glenn S. Boehnlein) | Advisor to the Chief Executive Officer (Glenn S. Boehnlein) | April 1, 2025 | Retirement from CFO role and transition to advisory capacity |
| Director | Emmanuel P. Maceda | May 8, 2025 | Election to the Board | |
| Director | Allan C. Golston | May 8, 2025 | Did not stand for reelection |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Composition | Appointment of two new independent directors (Emmanuel P. Maceda in 2025 and Rachel M. Ruggeri in 2024) in the last two years, reflecting regular Board refreshment. | Ongoing | Enhances board diversity of experience and viewpoints, strengthening oversight capabilities. |
| Clawback Policy | Adoption of a separate, mandatory clawback policy regarding accounting restatements in compliance with SEC rules and NYSE listing standards. | October 2023 | Strengthens accountability for executive officers and aligns compensation recovery with regulatory requirements, enhancing investor confidence. |
| Non-Employee Director Compensation | Target value of the annual stock award of restricted stock units will increase to $225,000 (from $215,000). | May 6, 2026 | Aims to maintain competitive compensation for non-employee directors, attracting and retaining high-caliber talent. |
| Non-Employee Director Stock Ownership Guidelines | Stock ownership guideline value for each non-employee director will increase to $650,000 (from $600,000). | May 6, 2026 | Further aligns the financial interests of non-employee directors with those of shareholders, promoting long-term value creation. |
| Board Leadership Structure | Continuation of Kevin A. Lobo serving in the combined role of Chair of the Board and Chief Executive Officer, with Sherilyn S. McCoy as Lead Independent Director. | Ongoing | Provides unified leadership while ensuring independent oversight through a robust Lead Independent Director role with clearly defined duties. |
Related Party Transactions
- The Company spent $1,215,000 in 2025 on functions and meetings at hotel, restaurant, and entertainment properties in Kalamazoo, Michigan, owned by Greenleaf Hospitality, which is 100% owned by Ms. Stryker's husband. The Board determined this relationship is not material and transactions were on arm's-length terms.
- The Company contracts for consulting services from Bain & Company, where director Emmanuel P. Maceda is a partner and serves as Chair. Payments from the Company to Bain & Company in 2025 did not exceed 2% of Bain & Company's consolidated gross revenue. The Board believes these transactions were on arm's-length terms.
Stakeholder Impact
- Shareholders benefit from strong financial performance, increased dividends, and performance-aligned executive compensation, as well as robust corporate governance practices.
- Employees are motivated by competitive compensation programs, including 401(k) and supplemental plans, and the company's commitment to corporate responsibility.
- Customers and suppliers are impacted by the company's strategic plan and operational performance, which aims to make healthcare better through responsible, sustainable practices.
- Regulatory bodies are addressed through the company's compliance with SEC rules, NYSE listing standards, and internal policies, including new clawback provisions.
Next Steps
- Shareholders to vote on the election of ten directors at the 2026 Annual Meeting on May 6, 2026.
- Shareholders to vote on the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026.
- Shareholders to conduct an advisory vote to approve named executive officer compensation.
- An updated risk assessment of the sales compensation program will be finalized in 2026, with findings to be disclosed in the 2027 proxy statement.
- Non-employee director fees and stock ownership guidelines will increase effective May 6, 2026.
- Proposals for inclusion in the 2027 proxy materials must be received by November 23, 2026.
- Director nominations for inclusion in the 2027 proxy materials (proxy access) must be received between October 24, 2026, and November 23, 2026.
- Other proposals or nominations for the 2027 Annual Meeting (advance notice) must be received between January 6, 2027, and February 5, 2027.
Key Dates
| Date | Description |
|---|---|
| 1974 | Ernst & Young LLP and its predecessor firms have been retained as the Company's independent auditor continuously since this year. |
| 1984 | Ronda E. Stryker joined the Board of Directors. |
| 1988 | Ronda E. Stryker became Vice Chair and Director of Greenleaf Trust. |
| 2011 | Kevin A. Lobo became Group President, Stryker Orthopaedics. |
| 2012 | Kevin A. Lobo became Chief Executive Officer and President; Sherilyn S. McCoy became Chief Executive Officer and Director of Avon Products, Inc. |
| 2013 | Andrew K. Silvernail joined the Board of Directors. |
| 2014 | Kevin A. Lobo became Chair, Chief Executive Officer and President; Lisa M. Skeete Tatum founded Landit, Inc. |
| 2015 | Giovanni Caforio, M.D. became Chief Executive Officer of Bristol-Myers Squibb; Semler Brossy Consulting Group, LLC engaged as independent compensation consultant. |
| 2017 | Mary K. Brainerd joined the Board of Directors; Giovanni Caforio, M.D. became Chairman of the Board of Bristol-Myers Squibb. |
| 2018 | Kevin A. Lobo became Chair and Chief Executive Officer of Stryker; Sherilyn S. McCoy joined the Board of Directors; Rajeev Suri joined the Board of Directors; Rachel M. Ruggeri became Chief Financial Officer and Corporate Secretary of Continental Mills, Inc. |
| 2020 | Giovanni Caforio, M.D. joined the Board of Directors; Lisa M. Skeete Tatum joined the Board of Directors. |
| 2021 | Rachel M. Ruggeri became Executive Vice President and Chief Financial Officer of Starbucks Corporation; Rajeev Suri became Chief Executive Officer and Director of Inmarsat. |
| 2022 | Independent auditor's lead audit partner rotated. |
| October 2023 | Board adopted a separate, mandatory clawback policy regarding accounting restatements. |
| December 29, 2023 | Date of Vanguard Group, Inc.'s Schedule 13G/A filing information. |
| December 31, 2023 | Date of BlackRock, Inc.'s Schedule 13G/A filing information. |
| February 13, 2024 | The Vanguard Group, Inc. filed Schedule 13G/A. |
| January 29, 2024 | BlackRock, Inc. filed Schedule 13G/A. |
| 2024 | Rachel M. Ruggeri joined the Board of Directors. |
| mid-2024 | Semler Brossy conducted a market benchmarking study for NEO compensation. |
| January 17, 2025 | Preston W. Wells received a stock award at the conclusion of his tenure as an internal employee resource group leader. |
| January 24, 2025 | Letter agreement entered with Mr. Boehnlein regarding his retirement and transition to an advisory role. |
| January 27, 2025 | Letter agreement entered with Mr. Wells regarding his promotion to Vice President, Chief Financial Officer. |
| February 5, 2025 | Performance stock units and stock options awarded to NEOs (except Mr. Boehnlein). |
| mid-February 2025 | Acquisition of Inari Medical, Inc. occurred. |
| March 1, 2025 | Effective date for annualized 2025 base salaries for most NEOs. |
| April 1, 2025 | Preston W. Wells became Vice President, Chief Financial Officer; Glenn S. Boehnlein retired from CFO role and transitioned to Advisor to CEO. |
| May 8, 2025 | Emmanuel P. Maceda was elected as a director; Allan C. Golston's directorship ended. |
| July 2025 | Board approved a financial counseling benefit for NEOs (other than Mr. Boehnlein) and other senior management. |
| second half of 2025 | Updated risk assessment of sales compensation program commenced. |
| December 31, 2025 | Fiscal year-end for financial statements and equity awards. |
| January 1, 2026 | Kevin A. Lobo's title changed to Chair and Chief Executive Officer; Spencer S. Stiles became President and Chief Operating Officer; Supplemental Plan participants have option for employee contributions to be paid prior to or following termination. |
| February 2026 | Audit Committee appointed Ernst & Young LLP as independent registered public accounting firm for 2026; 2026 compensation decisions for NEOs were made. |
| February 3, 2026 | Closing price of Common Stock ($360.82) used as exercise price for 2026 stock options. |
| February 4, 2026 | Restricted stock units granted to J. Andrew Pierce. |
| March 9, 2026 | Record date for shareholders entitled to vote at the 2026 Annual Meeting. |
| March 21, 2026 | 2023 Performance Stock Units vested and settled in Common Stock. |
| March 23, 2026 | Date of this Proxy Statement; solicitation of proxies began. |
| March 31, 2026 | Glenn S. Boehnlein's employment as Advisor to the Chief Executive Officer concludes. |
| May 5, 2026 | Deadline for internet or telephone proxy votes (11:59 p.m. Eastern Time). |
| May 6, 2026 | Date of the 2026 Annual Meeting of Shareholders; effective date for changes to non-employee director fees and stock ownership guidelines. |
| August 2026 | Audit Committee meeting to approve scope of audit engagement and estimated audit fees for Ernst & Young LLP. |
| October 24, 2026 | Earliest date for director nominations for inclusion in 2027 proxy materials (proxy access). |
| November 23, 2026 | Deadline for shareholder proposals for inclusion in 2027 proxy materials (SEC Rule 14a-8); latest date for director nominations for inclusion in 2027 proxy materials (proxy access). |
| January 6, 2027 | Earliest date for other proposals or nominations to be brought before the 2027 Annual Meeting (advance notice). |
| February 5, 2027 | Latest date for other proposals or nominations to be brought before the 2027 Annual Meeting (advance notice). |
| March 21, 2027 | One-third vesting date for restricted stock units granted to J. Andrew Pierce in 2026; 2024 PSUs vest. |
| March 21, 2028 | One-third vesting date for restricted stock units granted to J. Andrew Pierce in 2026; 2025 PSUs vest. |
| early 2029 | 2026 performance stock units will be settled in Common Stock. |
| March 21, 2029 | Final one-third vesting date for restricted stock units granted to J. Andrew Pierce in 2026. |
Recommendation
buyThe filing presents strong 2025 financial results, including double-digit growth in net sales and adjusted net earnings per diluted share, and a 200% payout on long-term performance stock units, indicating excellent execution against strategic goals. The company demonstrates robust corporate governance and a compensation structure that effectively aligns executive incentives with shareholder value creation. These factors suggest continued positive momentum and make Stryker an attractive investment.
Keywords
Stryker, SYK, SEC Filing, Proxy Statement, Financial Performance, Executive Compensation, Corporate Governance, Net Sales, Net Earnings, Adjusted Net Earnings, Dividends, Shareholder Meeting, Medical Technology, Orthopaedics, MedSurg, Neurotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.